CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Mavyretdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03523871
NCT03523871Phase 2Completed
CompareCT.gov

A Single-center Pilot Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

NYU Langone Health·interventional·Posted May 14, 2018·Updated Sep 5, 2021

In Brief

A Phase 2 clinical trial evaluating Mavyret for Hepatitis C. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Patients who are Hepatitis C Negative (HCV negative) and are on the waiting list for a lung transplant at NYULH who consent to participate in this study will receive a lung transplant from a deceased donor that is HCV positive. Patients will initiate treatment for HCV with the pan-genotypic agent, Mavyret, on the day of surgery and will complete the full 8-week treatment course. Patients will be monitored post-transplant for the development of viremia, and for the time course of clearance of viremia among those who develop viremia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 14, 2018
Enrollment StartMay 12, 2018
Primary CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.1 years ago

Interventions

Mavyretdrug

Patients will be on 8 weeks of Mavyret